While high-dose immunosuppressive therapy is not without complications, we must remember that research is rarely linear and every step closer is a step closer – we learn a bit more and refine the process with each step as our understanding of all of the elements which make up our health, recover and illness are slowly puzzled together like a patch-work quilt…
Encouraging results help set stage for larger studies.
New clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person’s own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis (MS), an autoimmune disease in which the immune system attacks the central nervous system.
Five years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions. Notably, participants did not take any MS medications after receiving HDIT/HCT. Other studies have indicated that currently available MS drugs have lower success rates.
The trial, called HALT-MS, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN). The researchers published three-year results from the study in December 2014, and the final five-year results appear online Feb. 1 in Neurology, the medical journal of the American Academy of Neurology.
12/12/2013 – Dr Oz and Dr Tisch discuss MS and stem cells http://www.doctoroz.com/episode/meredith-vieiras-family-health-battle?